甲状腺眼病药物1/2期阳性数据后Acelyrin获得

2024-03-20 22:09

Acelyrin (NASDAQ:SLRN) shares rose +2.89% to $8.19 on Wednesday, after announcing positive early-stage study data from an ongoing trial of its drug lonigutamab, in treating thyroid eye disease.
Lonigutamab is a subcutaneously delivered humanized IgG1 monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R), a validated mechanism of action for the treatment for TED.

In the Phase 1/2 trial, lonigutamab demonstrated rapid improvements in proptosis and clinical activity score at the first measurement – within three weeks after the first subcutaneous dose, Acelyrin (SLRN) added.
“The data support our hypothesis that lonigutamab has the potential to optimize benefit-risk by enabling longer-term subcutaneous dosing to increase depth and durability of clinical response while attempting to limit safety liabilities by avoiding the high maximal concentrations resulting from IV administration, while maintaining optimal therapeutic levels,” Acelyrin CEO Shao-Lee Lin said.
Phase 2b/3 trial is planned to be initiated in the second half of 2024, designed to be the first of two registrational trials in TED.
SLRN +9.05% premarket to $8.68.
Source: Press Release

More on Acelyrin